Back to Research Hub
BioCryst Pharmaceuticals, Inc.
BCRX
$10.09-0.09 (-0.84%)
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and…
StreetsValue research for BioCryst Pharmaceuticals, Inc. (BCRX)
Members get the full report for BioCryst Pharmaceuticals, Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.